Page 120 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 5
References
1. Pfreundschuh M, Ho AD, Cavallin-Stahl E et al (2008) Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol . 9:435–444.
2. Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 32:3048–3058.
3. Cheebsumon P, Boellaard R, de Ruysscher D et al (2012) Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology. EJNMMI Res. 2:56.
4. Frings V, de Langen AJ, Smit EF et al (2010) Repeatability of metabolically active volume measurements with 18F-FDG and 18FFLT PET in non-small cell lung cancer. J Nucl Med. 51:1870– 1877.
5. Wang XY, Zhao YF, Liu Y, Yang YK, Zhu Z, Wu N (2017) Comparison of different automated lesion delineation methods for metabolic tumor volume of 18F-FDG PET/CT in patients with stage I lung adenocarcinoma. Medicine (Baltimore). 96(51):e9365.
6. Cottereau AS, Lanic H, Mareschal S et al (2016) Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res. 22:3801–3809.
7. Mikhaeel NG, Smith D, Dunn JT et al (2016) Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 43:1209–1219.
8. Sasanelli M, Meignan M, Haioun C et al (2014) Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 41:2017–2022.
9. Song MK, Chung JS, Shin HJ et al (2012) Clinical significance of metabolic tumor volume by PET/ CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 91:697–703.
10. Ilyas H, Mikhaeel NG, Dunn JT et al (2018) Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 45:1142– 1154.
11. Kurtz DM, Green MR, Bratman SV et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 125:3679–3687.
12. Meignan M, Sasanelli M, Casasnovas RO et al (2014) Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 41:1113–1122.
13. Kostakoglu L, Chauvie S (2018) Metabolic tumor volume metrics in lymphoma. Semin Nucl Med. 48:50–66.
14. Cottereau AS, Hapdey S, Chartier L et al (2017) Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma. J Nucl Med. 58:276–281.
15. Kanoun S, Tal I, Berriolo-Riedinger A et al (2015) Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS One. 10:e0140830.
16. Boellaard R (2018) Quantitative oncology molecular analysis suite: ACCURATE [abstract]. J Nucl Med. 59(suppl.1):1753.
17. Frings V, van Velden FH, Velasquez LM et al (2014) Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 273:539–548.
18. Schaefer A, Vermandel M, Baillet C et al (2016) Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation. Eur J Nucl Med Mol Imaging. 43:911–924.
118